[Decision-making about gout by physicians of China and influencing factors thereof].

Zhonghua Yi Xue Za Zhi

Department of General Internal Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.

Published: July 2006

Objective: To investigate the decision-making about gout by physicians of China and influencing factors thereof.

Methods: A questionnaire survey, including 13 multiple choice questions, was divided into 2 stages. The first/stage questionnaire survey was conducted among 121 physicians of the departments of internal medicine and rheumatology respectively during the grand ward rounds, and the second-stage questionnaire survey was conducted among 75 physicians attending a national continuous medical education (CME) workshop of rheumatology. The data thus collected were pooled and analyzed by logistic regression models.

Results: 62 effective questionnaires were collected in the first/stage survey, and 38 effective questionnaires were collected in the second-stage survey, both with a missing rate < 10%. 78.3% of the respondents considered aspiration of the joint fluid as critical for the definitive diagnosis of gout, but only 2.4% of the respondents did so frequently. When treating acute gout in otherwise healthy patients, 69.2% of the respondents preferred oral colchicine, and while treating the patients with renal dysfunction, 41.7% of the respondents used corticosteroids or corticotrophin as the first choice. For long-term uric acid-lowering therapy, 99 of them (82.5%) described a variety of incorrect indications, 107 of them (89.2%) initiated the treatment too early (< or = 2 weeks after the remission), and 92 of them (76.7%) failed to sustain the treatment for at least 5 years. Only 17 physicians (14.2%) used prophylaxis while initiating the uric acid-lowering treatment and only 7 of them (5.8%) selected a prophylaxis time of 7 approximately 12 months. Multiple logistic regression analysis showed that only CMD on gout was associated with correct diagnosis strategy (OR 7.1, 95% CI 2.1 approximately 23.7).

Conclusion: The management of gout by the physicians in China is often not consistent with that generally accepted internationally. High quality CME may improve the decision-making ability of physicians.

Download full-text PDF

Source

Publication Analysis

Top Keywords

gout physicians
12
physicians china
12
questionnaire survey
12
china influencing
8
influencing factors
8
survey conducted
8
logistic regression
8
effective questionnaires
8
questionnaires collected
8
uric acid-lowering
8

Similar Publications

Article Synopsis
  • Pegloticase effectively lowers serum urate levels in patients with uncontrolled gout, but its use is limited by the development of anti-drug antibodies.
  • Co-administration of methotrexate (MTX) was found to enhance the urate-lowering response and reduce the risk of infusion reactions, benefiting patients with limited treatment options.
  • In a study involving 100 patients, those receiving pegloticase and MTX showed greater improvements in gout response rates compared to those receiving pegloticase and a placebo after 52 weeks of treatment.
View Article and Find Full Text PDF

Improving Gout Care in a Canadian Academic Medical Center Through a Multidisciplinary Nurse-Led Protocol.

J Rheumatol

December 2024

P. Dagenais, MD, PhD, Department of Medicine, Rheumatology Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Objective: Following Health Canada's knowledge translation framework, we report the results of a clinical audit from 2012 to 2015 followed by a multidisciplinary, nurse-led gout care protocol with a treat-to-target (T2T) strategy implemented in April 2018.

Methods: A clinical audit with chart reviewing was completed for adults with gout and urate-lowering therapy (ULT) indication at the Centre Hospitalier Universitaire de Sherbrooke. A nurse-led treatment algorithm using allopurinol was then developed.

View Article and Find Full Text PDF

Topiroxostat-A Safer Uricostatic Drug with Enhanced Renal Protection: A Narrative Review.

J Assoc Physicians India

November 2024

Professor and Head, Department of Nephrology, M S Ramaiah Medical College, Bengaluru, Karnataka, India.

Topiroxostat, a selective xanthine oxidase inhibitor, effectively reduces serum urate levels in hyperuricemia patients with or without gout. The present narrative review aims to evaluate the existing evidence regarding the effectiveness of topiroxostat on renal function in patients with and without kidney disease. A systematic search was conducted to identify relevant studies on renal function and topiroxostat published between 2005 and 2023.

View Article and Find Full Text PDF
Article Synopsis
  • * Findings show that in 2021, the overall prevalence was 13.6%, with significantly higher rates for men (24.3%) compared to women (2.6%), and marked regional differences across the country.
  • * Male sex, older age, and certain health conditions like hypertension and obesity are linked to higher hyperuricemia prevalence, highlighting the need for increased awareness and management of this issue in China's developed areas.
View Article and Find Full Text PDF

Objective: The objective of this study was to assess the burden of gout flares and examine associated patient characteristics and outcomes in a sample of US adults.

Methods: Data were collected via an online survey of US adults ≥18 years using a random stratified sampling framework. Participants with gout completed questions about treatments, serum urate (SU) levels, severity, satisfaction with control, and gout flares.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!